Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the therapeutic efficacy and the safety for the treatments on malignant melanoma
by combining semiantigen dinitrophenyl (DNP) in situ immunotherapy and laser therapy, and
carry out monitoring on related immunological parameters of the patients.
72 patients with stage III (b or c) or stage IV skin (which could not be excised by
operations) malignant melanoma were treated by combining simple semiantigen DNP in situ
immunotherapy and laser therapy respectively. The changes in peripheral blood CD4+CD25+Treg
regulatory T cells (Treg), CD8+T, CD4+ T effector cells, IL-10, TGF-β and other inhibitory
cytokines of the patients were detected, the changes in anti-DNP IgG antibody titer was
monitored, the relationship between delayed-type hypersensitivity (DTH) and survival was
observed, and results of clinical follow-ups were also examined.